The C-terminal HCN4 variant P883R alters channel properties and acts as genetic modifier of atrial fibrillation and structural heart disease.


Journal

Biochemical and biophysical research communications
ISSN: 1090-2104
Titre abrégé: Biochem Biophys Res Commun
Pays: United States
ID NLM: 0372516

Informations de publication

Date de publication:
29 10 2019
Historique:
received: 15 08 2019
accepted: 26 08 2019
pubmed: 5 9 2019
medline: 27 5 2020
entrez: 5 9 2019
Statut: ppublish

Résumé

Atrial fibrillation (AF) is the most frequent sustained arrhythmia and can lead to structural cardiac changes, known as tachycardia-induced cardiomyopathy (TIC). HCN4 is implicated in spontaneous excitation of the sinoatrial node, while channel dysfunction has been associated with sinus bradycardia, AF and structural heart disease. We here asked whether HCN4 mutations may contribute to the development of TIC, as well. Mutation scanning of HCN4 in 60 independent patients with AF and suspected TIC followed by panel sequencing in carriers of HCN4 variants identified the HCN4 variant P883R [minor allele frequency (MAF): 0,88%], together with the KCNE1 variant S38G (MAF: 65%) in three unrelated patients. Family histories revealed additional cases of AF, sudden cardiac death and cardiomyopathy. Patch-clamp recordings of HCN4-P883R channels expressed in HEK293 cells showed remarkable alterations of channel properties shifting the half-maximal activation voltage to more depolarized potentials, while channel deactivation was faster compared to wild-type (WT). Co-transfection of WT and mutant subunits, resembling the heterozygous cellular situation of our patients, revealed significantly higher current densities compared to WT. In conclusion HCN4-P883R may increase ectopic trigger and maintenance of AF by shifting the activation voltage of I

Identifiants

pubmed: 31481236
pii: S0006-291X(19)31679-1
doi: 10.1016/j.bbrc.2019.08.150
pii:
doi:

Substances chimiques

HCN4 protein, human 0
Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels 0
Muscle Proteins 0
Potassium Channels 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

141-147

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Auteurs

Isabel Weigl (I)

Department of Cardiology, Medical University Hospital Heidelberg, INF 410, D-69120, Heidelberg, Germany; Institute for Physiology and Pathophysiology, University of Heidelberg, INF 326, D-69120, Heidelberg, Germany; DZHK (German Centre for Cardiovascular Research), Partner site Heidelberg/Mannheim, INF 410, D-69120, Heidelberg, Germany.

Pascal Geschwill (P)

Institute for Physiology and Pathophysiology, University of Heidelberg, INF 326, D-69120, Heidelberg, Germany.

Miriam Reiss (M)

Department of Cardiology, Medical University Hospital Heidelberg, INF 410, D-69120, Heidelberg, Germany; DZHK (German Centre for Cardiovascular Research), Partner site Heidelberg/Mannheim, INF 410, D-69120, Heidelberg, Germany.

Claus Bruehl (C)

Institute for Physiology and Pathophysiology, University of Heidelberg, INF 326, D-69120, Heidelberg, Germany.

Andreas Draguhn (A)

Institute for Physiology and Pathophysiology, University of Heidelberg, INF 326, D-69120, Heidelberg, Germany.

Michael Koenen (M)

Department of Cardiology, Medical University Hospital Heidelberg, INF 410, D-69120, Heidelberg, Germany; Department of Molecular Neurobiology, Max-Planck-Institute for Medical Research, Jahnstraße 29, D-69120, Heidelberg, Germany.

Farbod Sedaghat-Hamedani (F)

Department of Cardiology, Medical University Hospital Heidelberg, INF 410, D-69120, Heidelberg, Germany; DZHK (German Centre for Cardiovascular Research), Partner site Heidelberg/Mannheim, INF 410, D-69120, Heidelberg, Germany.

Benjamin Meder (B)

Department of Cardiology, Medical University Hospital Heidelberg, INF 410, D-69120, Heidelberg, Germany; DZHK (German Centre for Cardiovascular Research), Partner site Heidelberg/Mannheim, INF 410, D-69120, Heidelberg, Germany.

Dierk Thomas (D)

Department of Cardiology, Medical University Hospital Heidelberg, INF 410, D-69120, Heidelberg, Germany; DZHK (German Centre for Cardiovascular Research), Partner site Heidelberg/Mannheim, INF 410, D-69120, Heidelberg, Germany.

Hugo A Katus (HA)

Department of Cardiology, Medical University Hospital Heidelberg, INF 410, D-69120, Heidelberg, Germany; DZHK (German Centre for Cardiovascular Research), Partner site Heidelberg/Mannheim, INF 410, D-69120, Heidelberg, Germany.

Patrick A Schweizer (PA)

Department of Cardiology, Medical University Hospital Heidelberg, INF 410, D-69120, Heidelberg, Germany; DZHK (German Centre for Cardiovascular Research), Partner site Heidelberg/Mannheim, INF 410, D-69120, Heidelberg, Germany. Electronic address: patrick.schweizer@med.uni-heidelberg.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH